CN114008035A - 一种shp2磷酸酶变构抑制剂 - Google Patents
一种shp2磷酸酶变构抑制剂 Download PDFInfo
- Publication number
- CN114008035A CN114008035A CN202080043751.5A CN202080043751A CN114008035A CN 114008035 A CN114008035 A CN 114008035A CN 202080043751 A CN202080043751 A CN 202080043751A CN 114008035 A CN114008035 A CN 114008035A
- Authority
- CN
- China
- Prior art keywords
- dihydrospiro
- indene
- tert
- compound
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 title claims abstract description 11
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 title claims abstract description 11
- 229940125528 allosteric inhibitor Drugs 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000003287 optical effect Effects 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000003281 allosteric effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229940125812 SHP2 phosphatase inhibitor Drugs 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 90
- 239000000047 product Substances 0.000 description 77
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 49
- 125000001841 imino group Chemical group [H]N=* 0.000 description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- 239000002904 solvent Substances 0.000 description 34
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000012043 crude product Substances 0.000 description 28
- 238000004440 column chromatography Methods 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- -1 (R) -N- ((S) -5-cyano-1, 3-dihydrospiro [ indene-2, 4' -piperidin ] -3-yl) -2-methylpropane-2-sulfinamide trifluoroacetate Chemical compound 0.000 description 20
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 16
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- IXEXQYZAPGSKJC-UHFFFAOYSA-N ethyl 3-chloro-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxylate Chemical compound ClC=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)C(=O)OCC IXEXQYZAPGSKJC-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- YMFWUPIAKBJSTB-CQWFHMBZSA-N CC(C)(C)[S@@](=O)N[C@@H]1C2=CC=CC=C2CC13CCNCC3.C(=O)(C(F)(F)F)O Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1C2=CC=CC=C2CC13CCNCC3.C(=O)(C(F)(F)F)O YMFWUPIAKBJSTB-CQWFHMBZSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- GHRIDABVKDEQNS-UHFFFAOYSA-N ethyl 6-bromo-3-chloro-5-methylpyrazine-2-carboxylate Chemical compound BrC1=C(N=C(C(=N1)C(=O)OCC)Cl)C GHRIDABVKDEQNS-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XWTMEQYXJSJHHO-JOCHJYFZSA-N 3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxamide Chemical compound C1(C(=O)N)=NC(C2=C(C(=CC=C2)Cl)Cl)=C(N=C1N1CCC2(CC1)CC1=CC=CC=C1[C@H]2N)C XWTMEQYXJSJHHO-JOCHJYFZSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- OFJNGXHQTKATOD-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl OFJNGXHQTKATOD-XMMPIXPASA-N 0.000 description 4
- QZVPQHQOTGSUAB-HSZRJFAPSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C#N)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C#N)C5=C(C(=CC=C5)Cl)Cl QZVPQHQOTGSUAB-HSZRJFAPSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WRHUDFRWZFBPEF-UHFFFAOYSA-N methanesulfonamide;2,2,2-trifluoroacetic acid Chemical compound CS(N)(=O)=O.OC(=O)C(F)(F)F WRHUDFRWZFBPEF-UHFFFAOYSA-N 0.000 description 4
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- LOCGPWGCRVKCFN-UHFFFAOYSA-N (2-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(Cl)=C1 LOCGPWGCRVKCFN-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XBRNQAVLAWNHIC-UHFFFAOYSA-N 4-[(3-bromophenyl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1=CC=CC(Br)=C1 XBRNQAVLAWNHIC-UHFFFAOYSA-N 0.000 description 3
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 3
- XPGPDCNYCNPBKC-UHFFFAOYSA-N CC1=C(N=C(C(=N1)Cl)C(=O)N)C2=C(C(=CC=C2)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)Cl)C(=O)N)C2=C(C(=CC=C2)Cl)Cl XPGPDCNYCNPBKC-UHFFFAOYSA-N 0.000 description 3
- GEGXIKLXHRPATG-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl GEGXIKLXHRPATG-XMMPIXPASA-N 0.000 description 3
- IRJJRQQUUAVVAO-AJWVYOOVSA-N C[C@@H](CC1=CC=C(CC(CC2)(CCN2C2=NC(C)=C(C(C=CC=C3Cl)=C3Cl)N=C2CO)C2N)C2=C1)O Chemical compound C[C@@H](CC1=CC=C(CC(CC2)(CCN2C2=NC(C)=C(C(C=CC=C3Cl)=C3Cl)N=C2CO)C2N)C2=C1)O IRJJRQQUUAVVAO-AJWVYOOVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- TYIKXPOMOYDGCS-UHFFFAOYSA-N (2,3-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1Cl TYIKXPOMOYDGCS-UHFFFAOYSA-N 0.000 description 2
- MJADWSULPPPIKV-UOBPVEMNSA-N (R)-N-[(1S)-1'-[3-cyano-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1-yl]-2-methylpropane-2-sulfinamide Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N[S@](=O)C(C)(C)C)C#N)C5=C(C(=CC=C5)Cl)Cl MJADWSULPPPIKV-UOBPVEMNSA-N 0.000 description 2
- CJUMDGADQJSSKK-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1=CC=C(Br)C=C1 CJUMDGADQJSSKK-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- JEDALECUOKHQDK-UHFFFAOYSA-M 4-ethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylate Chemical compound CCC1(C([O-])=O)CCN(C(=O)OC(C)(C)C)CC1 JEDALECUOKHQDK-UHFFFAOYSA-M 0.000 description 2
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- TWMWCGFADRCABH-UHFFFAOYSA-N C1=CC(=C(C(=C1)Cl)Cl)C2=CN=C(C(=N2)C(=O)O)Cl Chemical compound C1=CC(=C(C(=C1)Cl)Cl)C2=CN=C(C(=N2)C(=O)O)Cl TWMWCGFADRCABH-UHFFFAOYSA-N 0.000 description 2
- GYXBQFJYNLGHKR-JOCHJYFZSA-N C1CN(CCC12CC3=CC=CC=C3[C@H]2N)C4=NC=C(N=C4CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound C1CN(CCC12CC3=CC=CC=C3[C@H]2N)C4=NC=C(N=C4CO)C5=C(C(=CC=C5)Cl)Cl GYXBQFJYNLGHKR-JOCHJYFZSA-N 0.000 description 2
- BWEBPVJEQZYIIZ-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(C)(CC(C=CC=N2)=C2Cl)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(C)(CC(C=CC=N2)=C2Cl)CC1)=O BWEBPVJEQZYIIZ-UHFFFAOYSA-N 0.000 description 2
- UFNCGVYDEUDNNT-CRICUBBOSA-N CC(C)(C)[S@@](=O)N[C@@H]1C2=C(CC13CCNCC3)C=CC(=C2)C(C)(C)O Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1C2=C(CC13CCNCC3)C=CC(=C2)C(C)(C)O UFNCGVYDEUDNNT-CRICUBBOSA-N 0.000 description 2
- GDEZYZDCCSOPGY-UHFFFAOYSA-N CC1=C(N=C(C(=N1)Cl)C#N)C2=C(C(=CC=C2)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)Cl)C#N)C2=C(C(=CC=C2)Cl)Cl GDEZYZDCCSOPGY-UHFFFAOYSA-N 0.000 description 2
- WAIQKUOAWIADDP-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl WAIQKUOAWIADDP-XMMPIXPASA-N 0.000 description 2
- KKPSDXXWXQDTEQ-HSZRJFAPSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)CO)C5=C(C(=CC=C5)Cl)Cl KKPSDXXWXQDTEQ-HSZRJFAPSA-N 0.000 description 2
- WTHHBYBPEKRUGV-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl WTHHBYBPEKRUGV-XMMPIXPASA-N 0.000 description 2
- CTXKUHGOKVCLOB-OAQYLSRUSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(C(=NC=C5)N)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(C(=NC=C5)N)Cl CTXKUHGOKVCLOB-OAQYLSRUSA-N 0.000 description 2
- XKBSKPHBTJXQPJ-OAQYLSRUSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(N=CC=C5)C(F)(F)F Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(N=CC=C5)C(F)(F)F XKBSKPHBTJXQPJ-OAQYLSRUSA-N 0.000 description 2
- UZVJZUIZMMWFBB-UHFFFAOYSA-N CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=CC(=NC(=C2Cl)Cl)NC(=O)OC(C)(C)C Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=CC(=NC(=C2Cl)Cl)NC(=O)OC(C)(C)C UZVJZUIZMMWFBB-UHFFFAOYSA-N 0.000 description 2
- BICBJYACLFTHNF-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl BICBJYACLFTHNF-RUZDIDTESA-N 0.000 description 2
- IWSKZIKVNZLDSD-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl IWSKZIKVNZLDSD-RUZDIDTESA-N 0.000 description 2
- FASNQTFTDIKYFO-XMMPIXPASA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)C)C5=C(C(=CC=C5)Cl)Cl FASNQTFTDIKYFO-XMMPIXPASA-N 0.000 description 2
- VNKIULREMCWXAZ-AREMUKBSSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)C)C5=C(C(=CC=C5)Cl)Cl VNKIULREMCWXAZ-AREMUKBSSA-N 0.000 description 2
- KZJKGMFEAUUILD-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl KZJKGMFEAUUILD-RUZDIDTESA-N 0.000 description 2
- DQSDUDDUGGAGPK-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl DQSDUDDUGGAGPK-RUZDIDTESA-N 0.000 description 2
- KACLWGCPUMDUHK-JOCHJYFZSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(C(=NC=C5)N)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(C(=NC=C5)N)Cl KACLWGCPUMDUHK-JOCHJYFZSA-N 0.000 description 2
- VJOIPRJLVQYCLI-JOCHJYFZSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(N=CC=C5)C(F)(F)F Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(N=CC=C5)C(F)(F)F VJOIPRJLVQYCLI-JOCHJYFZSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- DKKQZPVCISDBHD-HSZRJFAPSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound C(C1=NC(C2=C(C(=CC=C2)Cl)Cl)=C(N=C1N1CCC2(CC1)[C@H](N)C1=C(C=CC=C1)C2)C)O DKKQZPVCISDBHD-HSZRJFAPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- GZHAHULRVVGLSE-XMMPIXPASA-N ethyl 3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxylate Chemical compound C1(C(=O)OCC)=NC(=C(N=C1N1CCC2([C@H](N)C3=C(C2)C=CC=C3)CC1)C)C1=C(C(=CC=C1)Cl)Cl GZHAHULRVVGLSE-XMMPIXPASA-N 0.000 description 2
- POYHGPKBZHOUBJ-UHFFFAOYSA-N ethyl 5-bromo-6-methyl-2-oxo-1h-pyrazine-3-carboxylate Chemical compound CCOC(=O)C1=NC(Br)=C(C)N=C1O POYHGPKBZHOUBJ-UHFFFAOYSA-N 0.000 description 2
- LZJZHTZAUNNQGU-UHFFFAOYSA-N ethyl 6-methyl-2-oxo-1h-pyrazine-3-carboxylate Chemical compound CCOC(=O)C1=NC=C(C)N=C1O LZJZHTZAUNNQGU-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- OQYGRYBPALDMPC-UHFFFAOYSA-N spiro[3h-indene-2,4'-piperidine]-1-one Chemical compound O=C1C2=CC=CC=C2CC11CCNCC1 OQYGRYBPALDMPC-UHFFFAOYSA-N 0.000 description 2
- JAVVVDPMHHHPQO-KWMCUTETSA-N tert-butyl (1S)-1-[[(R)-tert-butylsulfinyl]amino]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxylate Chemical compound C(C)(C)([S@@](=O)N[C@H]1C2(CCN(CC2)C(=O)OC(C)(C)C)CC2=C1C=CC=C2)C JAVVVDPMHHHPQO-KWMCUTETSA-N 0.000 description 2
- DYNFTZOGEORYHU-JGCGQSQUSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-5-(methanesulfonamido)spiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=C(C=C3)NS(=O)(=O)C DYNFTZOGEORYHU-JGCGQSQUSA-N 0.000 description 2
- GXWIIEFIDCPXTM-SSEXGKCCSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-5-cyanospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=C(C=C3)C#N GXWIIEFIDCPXTM-SSEXGKCCSA-N 0.000 description 2
- PDIIAMGIEONAGN-JGCGQSQUSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-6-(methanesulfonamido)spiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=CC(=C3)NS(=O)(=O)C PDIIAMGIEONAGN-JGCGQSQUSA-N 0.000 description 2
- HDDUCRQHFJPZLL-MUUNZHRXSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]iminospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=CC=CC=C3C2=N[S@](=O)C(C)(C)C HDDUCRQHFJPZLL-MUUNZHRXSA-N 0.000 description 2
- WRHWHEZSKPZFPH-UHFFFAOYSA-N tert-butyl 4-[(2-chloropyridin-3-yl)-hydroxymethyl]-4-methylpiperidine-1-carboxylate Chemical compound ClC1=NC=CC=C1C(C1(CCN(CC1)C(=O)OC(C)(C)C)C)O WRHWHEZSKPZFPH-UHFFFAOYSA-N 0.000 description 2
- KPVGSBWJGVRKFU-UHFFFAOYSA-N tert-butyl N-(5,6-dichloropyridin-2-yl)carbamate Chemical compound ClC=1C=CC(=NC=1Cl)NC(OC(C)(C)C)=O KPVGSBWJGVRKFU-UHFFFAOYSA-N 0.000 description 2
- UEYNRRQJJHZENW-UHFFFAOYSA-N tert-butyl n-(6-chloropyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(Cl)=N1 UEYNRRQJJHZENW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ABRTZUPJNVJMHP-UHFFFAOYSA-N (2,3-dichloropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC(Cl)=C1Cl ABRTZUPJNVJMHP-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical class C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- DVFVYGOJZOUJJB-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-[(4-bromophenyl)methyl]piperidine-1,4-dicarboxylate Chemical compound C=1C=C(Br)C=CC=1CC1(C(=O)OCC)CCN(C(=O)OC(C)(C)C)CC1 DVFVYGOJZOUJJB-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- GXZDYRYYNXYPMQ-UHFFFAOYSA-N 2-chloro-6-methylpyridine Chemical compound CC1=CC=CC(Cl)=N1 GXZDYRYYNXYPMQ-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- SMZAZDGFGOHROS-UHFFFAOYSA-N 3-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1Br SMZAZDGFGOHROS-UHFFFAOYSA-N 0.000 description 1
- IJOSVNBGIKAARU-UHFFFAOYSA-N 3-chloro-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1Cl IJOSVNBGIKAARU-UHFFFAOYSA-N 0.000 description 1
- GTTQRVGVEIXEHQ-UHFFFAOYSA-N 3-chloro-4-iodopyridin-2-amine Chemical compound NC1=NC=CC(I)=C1Cl GTTQRVGVEIXEHQ-UHFFFAOYSA-N 0.000 description 1
- SIFLLSPJESSXAF-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylchromen-2-one;phosphoric acid Chemical compound OP(O)(O)=O.FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C SIFLLSPJESSXAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PHBLTZGIJWYGRO-RUZDIDTESA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)CO)C5=C(C(=CC=C5)Cl)Cl PHBLTZGIJWYGRO-RUZDIDTESA-N 0.000 description 1
- RPODFFPFRWAEQL-UHFFFAOYSA-N CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(N=CC=C2)C(F)(F)F Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(N=CC=C2)C(F)(F)F RPODFFPFRWAEQL-UHFFFAOYSA-N 0.000 description 1
- FUWJGPBZKKQOOV-UHFFFAOYSA-N COC(=O)C1=NC(=CN=C1Cl)C2=C(C(=CC=C2)Cl)Cl Chemical compound COC(=O)C1=NC(=CN=C1Cl)C2=C(C(=CC=C2)Cl)Cl FUWJGPBZKKQOOV-UHFFFAOYSA-N 0.000 description 1
- IYOKQNJIWQMZPP-JOCHJYFZSA-N COC(=O)C1=NC(=CN=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C5=C(C(=CC=C5)Cl)Cl Chemical compound COC(=O)C1=NC(=CN=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C5=C(C(=CC=C5)Cl)Cl IYOKQNJIWQMZPP-JOCHJYFZSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 101150048674 PTPN11 gene Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- DBKKFIIYQGGHJO-UHFFFAOYSA-N diethyl 2-oxopropanedioate Chemical compound CCOC(=O)C(=O)C(=O)OCC DBKKFIIYQGGHJO-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- KSZBSQQDYGMAHA-UHFFFAOYSA-N ethyl 3-chloro-6-[3-chloro-2-(trifluoromethyl)pyridin-4-yl]-5-methylpyrazine-2-carboxylate Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(C(=NC=C2)C(F)(F)F)Cl KSZBSQQDYGMAHA-UHFFFAOYSA-N 0.000 description 1
- IRKBPZGHGQPMIW-UHFFFAOYSA-N ethyl 6-bromo-3-chloropyrazine-2-carboxylate Chemical compound CCOC(=O)c1nc(Br)cnc1Cl IRKBPZGHGQPMIW-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- MHJUNMARMFAUBI-UHFFFAOYSA-N n-phenyliminobenzamide Chemical compound C=1C=CC=CC=1C(=O)N=NC1=CC=CC=C1 MHJUNMARMFAUBI-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- RRAMTOSLXCIPSZ-UHFFFAOYSA-N tert-butyl 5-bromo-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC3=CC=C(Br)C=C3C2=O)CC1 RRAMTOSLXCIPSZ-UHFFFAOYSA-N 0.000 description 1
- FQZLNQAUUMSUHT-UHFFFAOYSA-N tert-butyl n,n-bis(2-chloroethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCl)CCCl FQZLNQAUUMSUHT-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Abstract
一种SHP2磷酸酶变构抑制剂,以及含有该抑制剂的药物,所述的SHP2磷酸酶变构抑制剂具有如下式(I)所示的结构,所述的SHP2磷酸酶变构抑制剂的光学异构体化合物或其药学上可接受的盐在制备用于***疾病的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (9)
- PCT国内申请,权利要求书已公开。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310905773.3A CN117209470A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310903760.2A CN117209475A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310907352.4A CN117209471A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019105151960 | 2019-06-14 | ||
CN201910515196 | 2019-06-14 | ||
CN2019110688218 | 2019-11-04 | ||
CN201911068821 | 2019-11-04 | ||
CN2020100567031 | 2020-01-17 | ||
CN202010056703 | 2020-01-17 | ||
CN2020105173727 | 2020-06-09 | ||
CN202010517372 | 2020-06-09 | ||
PCT/CN2020/095795 WO2020249079A1 (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310903760.2A Division CN117209475A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310907352.4A Division CN117209471A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310905773.3A Division CN117209470A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114008035A true CN114008035A (zh) | 2022-02-01 |
Family
ID=73780909
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310907352.4A Pending CN117209471A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202080043751.5A Pending CN114008035A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310905773.3A Pending CN117209470A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310903760.2A Pending CN117209475A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310907352.4A Pending CN117209471A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310905773.3A Pending CN117209470A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
CN202310903760.2A Pending CN117209475A (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220388977A1 (zh) |
EP (1) | EP3984999A4 (zh) |
JP (1) | JP7335003B2 (zh) |
KR (1) | KR20220061087A (zh) |
CN (4) | CN117209471A (zh) |
TW (1) | TW202112761A (zh) |
WO (1) | WO2020249079A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
CN115368373A (zh) * | 2021-05-21 | 2022-11-22 | 石药集团中奇制药技术(石家庄)有限公司 | 螺环类化合物及其用途 |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018041248A1 (zh) * | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019051084A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8575167B2 (en) * | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
EP3768668A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CN112839935A (zh) * | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
-
2020
- 2020-06-12 EP EP20822079.8A patent/EP3984999A4/en active Pending
- 2020-06-12 TW TW109119941A patent/TW202112761A/zh unknown
- 2020-06-12 US US17/618,835 patent/US20220388977A1/en active Pending
- 2020-06-12 CN CN202310907352.4A patent/CN117209471A/zh active Pending
- 2020-06-12 CN CN202080043751.5A patent/CN114008035A/zh active Pending
- 2020-06-12 WO PCT/CN2020/095795 patent/WO2020249079A1/zh unknown
- 2020-06-12 JP JP2021574766A patent/JP7335003B2/ja active Active
- 2020-06-12 KR KR1020227001357A patent/KR20220061087A/ko not_active Application Discontinuation
- 2020-06-12 CN CN202310905773.3A patent/CN117209470A/zh active Pending
- 2020-06-12 CN CN202310903760.2A patent/CN117209475A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018041248A1 (zh) * | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019051084A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
Also Published As
Publication number | Publication date |
---|---|
CN117209475A (zh) | 2023-12-12 |
WO2020249079A1 (zh) | 2020-12-17 |
JP2022535998A (ja) | 2022-08-10 |
KR20220061087A (ko) | 2022-05-12 |
EP3984999A1 (en) | 2022-04-20 |
US20220388977A1 (en) | 2022-12-08 |
EP3984999A4 (en) | 2023-11-22 |
CN117209470A (zh) | 2023-12-12 |
TW202112761A (zh) | 2021-04-01 |
CN117209471A (zh) | 2023-12-12 |
JP7335003B2 (ja) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
JP6506845B2 (ja) | B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 | |
KR102311573B1 (ko) | 브로모도메인 억제제 | |
JP6378171B2 (ja) | Dna−pk阻害剤 | |
JP6374959B2 (ja) | Dna−pk阻害剤 | |
JP2023071911A (ja) | Hpk1阻害剤およびそれを用いる方法 | |
CN116942663A (zh) | 用于治疗hbv的化合物 | |
KR20220067551A (ko) | 낭성 섬유증 막관통 전도도 조절자의 조절제 | |
CA2839675A1 (en) | Therapeutically active compositions and their methods of use | |
CN103097384A (zh) | 取代的咪唑并[1,2-a]嘧啶和吡啶 | |
JP6122877B2 (ja) | ユビキチン活性化酵素のピラゾロピリミジニル阻害剤 | |
CN112292374B (zh) | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 | |
KR20200081436A (ko) | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 | |
WO2019074809A1 (en) | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
JP2020523328A (ja) | Syk阻害薬及びその使用方法 | |
KR102205354B1 (ko) | 역형성 림프종 키나제(alk) 억제제로서의 인돌로퀴놀론 화합물 | |
WO2010109084A2 (fr) | DERIVES D'AZACARBOLINES 9H-PYRROLO[2,3-b:5,4-c']DIPYRIDINE, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE | |
IL291947A (en) | A compound with bromodomain-containing protein 4 (brd4) inhibitory activity, methods for its preparation and its uses | |
JP2021512055A (ja) | Tamファミリーキナーゼ/及びcsf1rキナーゼ阻害剤及びその用途 | |
CN117062813A (zh) | 一种多环化合物及其应用 | |
JP2022515309A (ja) | 置換アリール化合物、その製造方法及び用途 | |
CN104703599A (zh) | 作为蛋白激酶抑制剂的氨基异喹啉衍生物 | |
JP7406008B2 (ja) | Cdk9阻害剤としての多環式アミド系誘導体、その調製方法及び用途 | |
JP7451765B2 (ja) | Cdk阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途 | |
TW202214634A (zh) | 雜環化合物及其衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220201 |
|
RJ01 | Rejection of invention patent application after publication |